Home › Research › Clinical trials
Clinical trials
Every Alzheimer's trial in our copy of the ClinicalTrials.gov registry — completed, running and abandoned. Filter it, then follow the link to the official record.
If you are thinking about joining a trial
A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.
Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.
Showing 4,051–4,075 of 7,816 matching trials · page 163 of 313, 25 per page.
Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.
| Trial | Phase | Status | Enrolled | Sponsor | Last updated |
|---|---|---|---|---|---|
|
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans NCT03287765 18F-AV-1451 Runs in: United States · 1 site |
NA other |
COMPLETED | 54 | Tammie L. S. Benzinger, MD, PhD OTHER |
2023-05-08 |
|
Improving Well-Being for Older Adult Family Dementia Caregivers NCT03881631 Mindfulness Based Stress Reduction Program; Living Well Program Runs in: United States · 1 site |
NA other |
COMPLETED | 142 | University of Rochester OTHER |
2023-05-08 |
|
A Novel Computer-Based Functional Skills Assessment and Training Program NCT04679441 The Computerized Functional Skills Assessment and Training Program;... Runs in: United States · 2 sites |
PHASE2 other |
ACTIVE_NOT_RECRUITING | 180 | i-Function, Inc. INDUSTRY |
2023-05-08 |
|
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 NCT03810898 Radioligand [¹¹C]CHDI-00485180-R; Radioligand [¹¹C]CHDI-00485626 Runs in: Belgium · 1 site |
EARLY_PHASE1 other |
TERMINATED | 24 | CHDI Foundation, Inc. OTHER |
2023-05-06 |
|
The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome NCT04572477 [18F]THK-5351; [18F]AV-45 Runs in: Taiwan · 1 site |
PHASE2 other |
UNKNOWN | 200 | Chang Gung Memorial Hospital OTHER |
2023-05-06 |
|
The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke NCT04588649 THK-5351; AV-45 Runs in: Taiwan · 1 site |
PHASE2 other |
COMPLETED | 181 | Chang Gung Memorial Hospital OTHER |
2023-05-06 |
|
The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly NCT05845736 Antihypertensive Agents Runs in: France · 1 site |
NA other |
COMPLETED | 353 | Central Hospital, Nancy, France OTHER |
2023-05-06 |
|
Acceptance and Commitment Therapy (ACT) Tele-Counselling NCT05385458 ACT Intervention; Usual Care Runs in: Canada · 1 site |
NA other |
COMPLETED | 30 | University of New Brunswick OTHER |
2023-05-03 |
|
The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy NCT04309253 PMPBB3; AV45 Runs in: Taiwan · 1 site |
PHASE2 other |
UNKNOWN | 220 | Chang Gung Memorial Hospital OTHER |
2023-05-01 |
|
The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment NCT04318626 PMPBB3; THK5351 Runs in: Taiwan · 1 site |
PHASE2 other |
UNKNOWN | 80 | Chang Gung Memorial Hospital OTHER |
2023-05-01 |
|
Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects NCT03466736 [18F]flutemetamol PET scan Runs in: United States · 1 site |
NA other |
COMPLETED | 165 | University of Utah OTHER |
2023-04-28 |
|
Smart Environment Technology for Longitudinal Behavior Analysis and Intervention NCT01782157 Runs in: United States · 3 sites |
NA other |
COMPLETED | 44 | Washington State University OTHER |
2023-04-27 |
|
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy NCT03728582 Active tDCS plus Speech-Language Therapy; Sham tDCS plus Speech-Lan... Runs in: United States · 1 site |
NA other |
COMPLETED | 8 | Johns Hopkins University OTHER |
2023-04-27 |
|
Nursing Home Prevention of Injury in Dementia (NH PRIDE) NCT04242186 Injury Liaison Service Runs in: United States · 2 sites |
NA other |
COMPLETED | 140 | Hebrew SeniorLife OTHER |
2023-04-27 |
|
Cerebro Spinal Fluid Collection (CSF) NCT04844060 Lumbar punction Runs in: France · 1 site |
NA other |
RECRUITING | 10,000 | University Hospital, Strasbourg, France OTHER |
2023-04-27 |
|
Better Living With Non-memory-led Dementia NCT05525377 Better living with non-memory led dementia course Runs in: United Kingdom · 1 site |
NA other |
COMPLETED | 31 | University College, London OTHER |
2023-04-27 |
|
IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM) NCT02176226 IntelliCare Runs in: United States · 1 site |
NA other |
COMPLETED | 105 | Northwestern University OTHER |
2023-04-26 |
|
Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms NCT05438147 CT-100 DiNaMo; Care-as-Usual Runs in: United States · 1 site |
NA other |
COMPLETED | 114 | Click Therapeutics, Inc. INDUSTRY |
2023-04-26 |
|
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET NCT05831371 TEP FDG Runs in: France · 1 site |
NA other |
UNKNOWN | 87 | Central Hospital, Nancy, France OTHER |
2023-04-26 |
|
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease NCT05607615 Hydroxypropyl Beta Cyclodextrin; Placebo Runs in: United States · 5 sites |
PHASE2 other |
UNKNOWN | 90 | Cyclo Therapeutics, Inc. INDUSTRY |
2023-04-25 |
|
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly NCT00811122 11C-PIB PET Scan; FDG-PET Scan Runs in: United States · 1 site |
EARLY_PHASE1 other |
TERMINATED | 2 | University of Utah OTHER |
2023-04-24 |
|
Implications for Management of PET Amyloid Classification Technology NCT02778971 [18F]Flutemetamol Runs in: United States · 1 site |
NA other |
COMPLETED | 41 | University of Utah OTHER |
2023-04-24 |
|
A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease NCT03047694 tablet therapy; usual care Runs in: France · 2 sites |
NA other |
TERMINATED | 1 | Assistance Publique - Hôpitaux de Paris OTHER |
2023-04-24 |
|
Evaluation of Mobile Apps for Informal Caregivers of People Living With Dementia NCT05217004 Dementia Talk mobile application; CLEAR Dementia Care mobile application Runs in: Canada · 1 site |
NA other |
COMPLETED | 175 | University of Regina OTHER |
2023-04-21 |
|
Blood Microbiota Signature of Alzheimer's Disease NCT04841135 Multiomics quantification; Polysomnography Runs in: France · 1 site |
NA other |
UNKNOWN | 120 | University Hospital, Montpellier OTHER |
2023-04-20 |
This table is wider than a phone screen — swipe it sideways to see the rest.
Where these trials come from
- Registry
- ClinicalTrials.gov, pulled through their public API (v2)
- Trials in the file
- 7,816
- Source file
- trials.csv (3.8 MB, 7816 rows)
- Basis
- Measured These are registry records as submitted by each study's sponsor.
What could make this misleading
Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.
Always check the official record before acting on anything here. This is a summary, not medical advice.
From the research library
The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.
Clinical trials
- MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial
- Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
- Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
- Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease
- Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial